Abstract
Secretory phospholipase A2 group IIA (sPLA2-IIA) is an enzyme that hydrolyzes the sn-2 ester bond in glyceroacyl phospholipids present in lipoproteins and cell membranes. As many immunohistochemical studies reveal that the high expression of sPLA2-IIA in the tumorous tissue or plasma of cancer patients, though low expression in other cases, the enzyme is considered highly relevant with cancer development. Effort has been made to establish the mechanism of how sPLA2- IIA is involved in various cancers in order to understand its pathogenic role and to utilize it as a target for cancer diagnosis and therapy. This article specifically reviews recent studies regarding the relevance of sPLA2-IIA with various cancers and reported inhibitors of the protein.
Keywords: Cancer incidence, cell membranes, inhibitors, lipoproteins, sPLA2-IIA, therapeutic strategy.
Medicinal Chemistry
Title:A Concise Update on the Relevance of Secretory Phospholipase A2 Group IIA and its Inhibitors with Cancer
Volume: 13 Issue: 7
Author(s): Juan Chen, Long Ye*, Yu Sun and Yoshikazhu Takada
Affiliation:
- School of Chemistry and Chemical Engineering, Wuhan University of Science and Technology, Wuhan, Hubei Province 430081,China
Keywords: Cancer incidence, cell membranes, inhibitors, lipoproteins, sPLA2-IIA, therapeutic strategy.
Abstract: Secretory phospholipase A2 group IIA (sPLA2-IIA) is an enzyme that hydrolyzes the sn-2 ester bond in glyceroacyl phospholipids present in lipoproteins and cell membranes. As many immunohistochemical studies reveal that the high expression of sPLA2-IIA in the tumorous tissue or plasma of cancer patients, though low expression in other cases, the enzyme is considered highly relevant with cancer development. Effort has been made to establish the mechanism of how sPLA2- IIA is involved in various cancers in order to understand its pathogenic role and to utilize it as a target for cancer diagnosis and therapy. This article specifically reviews recent studies regarding the relevance of sPLA2-IIA with various cancers and reported inhibitors of the protein.
Export Options
About this article
Cite this article as:
Chen Juan , Ye Long*, Sun Yu and Takada Yoshikazhu , A Concise Update on the Relevance of Secretory Phospholipase A2 Group IIA and its Inhibitors with Cancer, Medicinal Chemistry 2017; 13 (7) . https://dx.doi.org/10.2174/1573406413666170209121317
DOI https://dx.doi.org/10.2174/1573406413666170209121317 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Liver X Receptors: Potential Novel Targets in Cardiovascular Diseases
Current Drug Targets - Cardiovascular & Hematological Disorders Exploring Optic Nerve Axon Regeneration
Current Neuropharmacology Structural Basis for Therapeutic Intervention of uPA/uPAR System
Current Drug Targets Hemodialysis Membranes for Acute and Chronic Renal Insufficiency
Current Neurovascular Research Advances of Mesenchymal Stem Cells Derived from Bone Marrow and Dental Tissue in Craniofacial Tissue Engineering
Current Stem Cell Research & Therapy Current Management of Intermittent Claudication: The Role of Pharmacological and Nonpharmacological Symptom-Directed Therapies
Current Vascular Pharmacology Subject Index to Volume 9
Current Pharmaceutical Design Endothelins and the Role of Endothelin Antagonists in the Management of Posttraumatic Vasospasm
Current Pharmaceutical Design Cystatin C in Cerebrovascular Disorders
Current Neurovascular Research ADAM17 as a Therapeutic Target in Multiple Diseases
Current Pharmaceutical Design Mass Spectrometric Analysis of F2-Isoprostanes: Markers and Mediators in Human Disease
Current Pharmaceutical Analysis Atrial Tachycardias Arising from the Atrial Appendages and Aortic Sinus of Valsalva
Current Cardiology Reviews Current Status of Carotid Stenting
Current Vascular Pharmacology Hypoperfusion of the Aortic Wall Secondary to Degeneration of Adventitial Vasa Vasorum Causes Abdominal Aortic Aneurysms
Current Drug Targets A Survey on Medical Image Segmentation
Current Medical Imaging Management and Outcomes of Aortic Dissection in Pregnancy with Marfan Syndrome: A Systematic Review
Current Vascular Pharmacology The Coronary Circulation in Cyanotic Congenital Heart Disease
Current Cardiology Reviews Utilizing Delta Opioid Receptors and Peptides for Cytoprotection: Implications in Stroke and Other Neurological Disorders
CNS & Neurological Disorders - Drug Targets Coarctation of the Aorta - An Evolution of Therapeutic Options
Current Cardiology Reviews Pharmacophore and 3D QSAR Study of TGFβ Inhibitors
Letters in Drug Design & Discovery